Spotlight on Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) in the Prevention of Premalignant Genital Lesions, Genital Cancer, and Genital Warts in Women

被引：0
|
作者：
Paul L. McCormack
Elmar A. Joura
机构：
[1] Adis,Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology
[2] a Wolters Kluwer Business,undefined
[3] Medical University of Vienna,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Human Papilloma Virus; Genital Wart; Seroconversion Rate; Human Papilloma Virus Vaccine; Human Papilloma Virus Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Quadrivalent human papilloma virus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®; Silgard®) is composed of virus-like particles (VLPs) formed by self-assembly of recombinant L1 capsid protein from each of HPV types 6, 11, 16, and 18. The VLPs are noninfectious, containing no DNA, and are highly immunogenic, inducing high levels of neutralizing antibodies against the particular HPV types when administered to animals or humans. Quadrivalent HPV vaccine is indicated for use from the age of 9 years for the prevention of premalignant genital lesions (cervical, vulvar, and vaginal), cervical cancer, and external genital warts (condyloma acuminata) causally related to certain oncogenic or specific HPV types.
引用
收藏
页码：339 / 343
页数：4
相关论文
共 42 条
  • [1] Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine (Gardasil®)A Review of its Use in the Prevention of Premalignant Genital Lesions, Genital Cancer and Genital Warts in Women
    Paul L. McCormack
    Elmar A. Joura
    Drugs, 2010, 70 : 2449 - 2474
  • [2] Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts
    Paul L. McCormack
    Drugs, 2014, 74 : 1253 - 1283
  • [3] Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 VaccineFor the Prevention of Genital Warts in Males
    Karly P. Garnock-Jones
    Anna R. Giuliano
    Drugs, 2011, 71 : 591 - 602
  • [4] Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil®)
    Siddiqui M.A.A.
    Perry C.M.
    Drugs, 2006, 66 (9) : 1263 - 1271
  • [5] The impact of human papillomavirus (HPV) types 6, 11 in women with genital warts
    Jamshidi, Mahin
    Shekari, Mohammad
    Nejatizadeh, Abdol Azim
    Malekzadeh, Keyanoush
    Baghershiroodi, Mahnaz
    Davudian, Parivash
    Dehghan, Farzaneh
    Jamshidi, Froogh
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2012, 286 (05) : 1261 - 1267
  • [6] The impact of human papillomavirus (HPV) types 6, 11 in women with genital warts
    Mahin Jamshidi
    Mohammad Shekari
    Abdol Azim Nejatizadeh
    Keyanoush Malekzadeh
    Mahnaz Baghershiroodi
    Parivash Davudian
    Farzaneh Dehghan
    Froogh Jamshidi
    Archives of Gynecology and Obstetrics, 2012, 286 : 1261 - 1267
  • [7] Human Papillomavirus Quadrivalent (types 6,11, 16,18) Recombinant Vaccine (Gardasil®): Profile Report
    M. Asif A. Siddiqui
    Caroline M. Perry
    BioDrugs, 2006, 20 : 313 - 316
  • [8] Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a guide to its use in the EU
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2015, 31 (1) : 1 - 8
  • [9] Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure
    Lurie, Samuel
    Mizrachi, Yossi
    Chodick, Gabi
    Katz, Rachel
    Schejter, Eduardo
    GYNECOLOGIC ONCOLOGY, 2017, 146 (02) : 299 - 304
  • [10] The relationship between the recurrence rate of genital warts and administration of quadrivalent human papilloma virus vaccine in women
    Asl, Fatemeh Momeni
    Ghaffari, Parvin
    Safari, Mitra
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2025, 111 (02)
12345